6 April 2020 - Biotechnology company CSL has weighed into the global race to fight the coronavirus by partnering with Japan’s Takeda Pharmaceutical Company to develop an old-fashioned but potentially effective treatment.

CSL, which is now the biggest company on the ASX, joined forces with Takeda to accelerate development of plasma-derived therapy to combat life-threatening complications of COVID-19.

The treatment, which will need regulatory approval, involves ­extracting antibodies from the plasma of people who have recovered from COVID-19 and developing that into a hyperimmune immunoglobulin medicine to help infected patients with serious complications fight the virus.

Read The Australian article